Freenome Stock

freenome.comHealthcare / BioTech & PharmaFounded: 2014Funding to Date: $1.35B

Freenome is a biotechnology company driven to provide the tools needed to detect, treat and prevent cancer using routing blood draw. This company was founded in 2014 by Gabe Otte, Riley Ennis, Charles Roberts and is headquartered in South San Francisco, CA. Freenome combines molecular biology with advanced computational biology and machine learning to help with early cancer detection.

Register To Buy and Sell Shares

For more details on financing and valuation for Freenome, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Freenome’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Freenome.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Freenome investors also invested in these private companies

Farallon Capital Management
EcoR1 Capital
Byers Capital
Longevity Vision Fund
Asset Management Ventures
Verily Life Sciences
Intermountain Ventures
Squarepoint Capital


Management Team

Charles Roberts
Co-Founder & Chief Growth Officer
Mike Nolan
Chief Executive Officer
Julie Tran
Chief People Officer
Michael Ash
Chief Commercial Officer
Charles Roberts
Chief Growth Officer
Gregory Chow
Chief Financial Officer
Cheng-Ho Jimmy Lin Ph.D
Chief Scientific Officer
Lance Baldo MD
Chief Medical Officer

Board Members

Amy Raimundo
Kaiser Permanente Ventures
Dror Berman
Innovation Endeavors
Ellen Hukkelhoven Ph.D
Perceptive Advisors
Michael Krepps
Peter Kolchinsky Ph.D
RA Capital Management

Frequently Asked Questions About Freenome’s Stock

Can you buy Freenome’s stock?
Freenome is not publicly traded on NYSE or NASDAQ in the U.S. To buy Freenome’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Freenome’s stock?
Yes, you can sell stock of a private company like Freenome. Forge can help you sell your Freenome stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Freenome’s stock price?
Freenome is a privately held company and therefore does not have a public stock price. However, you may access Freenome’s private market stock price with Forge Data.
What is Freenome’s stock ticker symbol?
Freenome does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Freenome swings $254m investment
To advance early cancer detection technology, Freenome received a fresh $254 million investment.
Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection
In a funding led by a16z Life Sciences Growth Fund, Freenome raised $254 million for its cancer detection platform.
Roche leads Freenome's $254M funding round for cancer-detecting blood tests
In early 2022, Freenome surpassed $1 billion in lifetime financing after raking in two nine-figure funding rounds barely a month apart, with plans to use the money to launch new studies of its cancer blood tests. Two years later, the company is adding to its coffers once again, with an eye toward both keeping those studies afloat and continuing to develop additional disease-detecting liquid biopsy tests. The latest funding round weighed in at $254 million, Freenome announced Thursday. It was led by Roche, which has participated in all of Freenome’s previous fundraising sessions and was also responsible for the $290 million contribution at the start of 2022 that brought Freenome’s total past the $1 billion mark.
Updated on: May 18, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.